Last Tuesday, I got three identical WhatsApp messages from former students. All three were tracking PV job openings at Indian pharma companies. All three noticed the same thing: Lupin posted four PV officer roles on Monday, then pulled them by Wednesday. Sun Pharma's Sikkim facility advertised two positions, then marked them "on hold" within 48 hours. Meanwhile, IQVIA Hyderabad added six new Drug Safety Associate openings and they are still live.
The reason? On July 6, 2026, the Federation of Pharma Entrepreneurs (FOPE) formally asked CDSCO to clarify pharmacovigilance obligations under revised Schedule M. This FOPE Schedule M pharmacovigilance clarification India 2026 situation has created genuine uncertainty in the job market. Some companies are hiring aggressively. Others have frozen PV recruitment until they know what compliance actually requires.
I have watched this pattern before. In 2018, similar regulatory ambiguity hit clinical data management. Some freshers panicked and abandoned pharma careers entirely. Others positioned themselves smartly and landed roles that would not have existed six months earlier. The difference? The second group understood what was actually happening and prepared for multiple scenarios.
That is exactly what I want to help you do right now.
What FOPE Asked CDSCO to Clarify (And Why It Matters for Your Job Hunt)
FOPE's request centers on one deceptively simple question: do Indian pharmaceutical manufacturers need dedicated in-house PV officers, or can they satisfy Schedule M requirements by outsourcing to CROs?
The revised Schedule M clearly mandates that manufacturers must have systems for adverse event reporting and signal detection. What it does not specify is whether these systems must be operated by employees on the company payroll or whether contractual arrangements with third-party providers satisfy the requirement.
FOPE asked for clarification on three specific points:
First: Can small and medium manufacturers with annual turnover below Rs 500 crore meet PV obligations through service agreements with established CROs? This matters because roughly 60% of Schedule M licensed manufacturers in India fall into this revenue category. If CDSCO says yes, CROs will see a surge in demand. If CDSCO says no, hundreds of mid-sized pharma companies will need to build internal PV teams from scratch.
Second: Can the "qualified person" requirement for PV be fulfilled by a designated contact at a CRO rather than a full-time employee? This question determines whether companies need to hire B.Pharm or M.Pharm graduates as permanent staff or can simply designate a CRO relationship manager as their compliance contact. The salary implications are significant. A permanent PV officer costs Rs 4.5 to 6 lakh per year plus benefits. A CRO service agreement might cost Rs 2 to 3 lakh annually per product portfolio.
Third: What documentation standards will satisfy GMP inspectors when PV functions are outsourced? This is the operational detail that keeps compliance officers awake at night. Even if outsourcing is permitted, companies need to know exactly what audit trail, training records, and oversight documentation they must maintain to prove effective supervision of their CRO partners.
CDSCO is expected to issue clarification by Q3 2026. Until then, hiring decisions at dozens of mid-sized Indian pharma companies are essentially on pause.
I spoke with the HR head at a Rs 800 crore Ahmedabad-based pharma company last week. She told me they have budget allocated for three PV officer positions but are waiting for CDSCO guidance before posting roles. This is not a hiring freeze. It is a hiring pause. The jobs are coming. We just do not know exactly what shape they will take.
Will This Make PV Jobs Scarcer or More Abundant in India?
Let me walk you through the two most likely scenarios and what each means for freshers.
Photo by ThisIsEngineering on Pexels
Photo by ThisIsEngineering on Pexels
Scenario 1: CDSCO mandates in-house PV teams
If this happens, we are looking at significant expansion of PV roles at Indian pharmaceutical companies. My conservative estimate, based on the number of Schedule M licensed manufacturers and typical PV team sizes, suggests this could create 2,000 to 3,000 new PV officer positions over the next 18 to 24 months.
These would primarily be entry-level roles at mid-sized companies in manufacturing hubs like Ahmedabad, Hyderabad, Baddi, and Sikkim. Salary ranges would likely fall between Rs 3.5 lakh and Rs 5 lakh per annum for freshers, with experienced professionals commanding Rs 6 to 8 lakh. The roles would focus heavily on domestic adverse event reporting, periodic safety update reports (PSURs), and maintaining pharmacovigilance system master files (PSMF).
Companies like Torrent Pharmaceuticals, Alkem Laboratories, Mankind Pharma, and Zydus Lifesciences would be the primary hiring engines. These organizations currently have limited in-house PV capabilities because they have historically outsourced these functions. A mandate for internal teams would force rapid buildout.
Scenario 2: CDSCO confirms CRO outsourcing satisfies requirements
If this happens, job growth shifts from pharma companies to CROs. Organizations like IQVIA, Parexel, Syneos Health, ICON, and Indian CROs like Syngene and Lambda Therapeutic Research would see increased demand for PV services.
This scenario would likely create more contract-based roles rather than permanent positions. Based on current CRO hiring patterns, we would expect an increase in 11-month contract positions at salary ranges of Rs 3 to 4.5 lakh per annum. These contracts often convert to permanent roles after one or two successful terms, but freshers should understand that job security looks different in this model.
The operational reality is that CROs can scale PV capacity faster than individual pharma companies. If 50 mid-sized pharma companies each need PV coverage for 20 products, a CRO can service all of them with a centralized team of 80 to 100 professionals. The same coverage would require 150 to 200 employees if each company built internal teams. This efficiency is why CROs can offer lower per-product costs while still providing competitive salaries.
Dr. Ramesh Kumar, a former CDSCO consultant who now advises pharmaceutical companies on regulatory compliance, shared his prediction with me last week. He believes CDSCO will likely adopt a hybrid model by 2027. Under this approach, large manufacturers (annual turnover above Rs 1,000 crore) would need dedicated in-house PV functions, while smaller manufacturers could demonstrate compliance through qualified CRO partnerships with specific documentation requirements.
This hybrid outcome would create opportunities in both channels, which is why I am advising freshers to build skills that work for either scenario.
Related reading on ClinPath:
- Drugs (Seventh Amendment) Rules 2026: What Schedule H2 Expansion Means for Regulatory Affairs Freshers in India
- Weekly Pharma Jobs Digest for Freshers in India 2025: CRA, PV, SAS & More
- FDA Tobacco Warning 2025: What Indian Pharma Freshers Need to Know About Regulatory Intelligence
What Skills PV Freshers Should Build Right Now (Regardless of Outcome)
While CDSCO figures out the regulatory framework, you should be building capabilities that make you hireable in either scenario. Let me be specific about what that means.
Master ICSR case processing in a major safety database
The two systems that dominate the Indian market are Oracle Argus Safety and Oracle Empirica. Most CROs in India use Argus, while some larger pharma companies have Empirica installations. Oracle offers free trial access to cloud versions of these platforms for educational purposes.
Spend time processing dummy cases. Create adverse event reports from scratch. Learn the workflow from case intake through medical review to regulatory submission. When an interviewer asks if you have hands-on experience with safety databases, you want to say "Yes, I have processed 35 cases in Argus Safety, including serious adverse events requiring expedited reporting," not "I learned about it in college."
Develop MedDRA coding proficiency to Level 4
MedDRA is the standardized medical terminology used globally for adverse event reporting. Accurate coding is one of the most common tasks assigned to entry-level PV professionals. The WHO Drug Global dictionary is available for practice, and there are free online resources that let you practice coding adverse events to the correct Preferred Term (PT) and Lowest Level Term (LLT).